GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » Sloan Ratio %

GNMLF (Genomma Lab InternacionalB de CV) Sloan Ratio % : 0.29% (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Genomma Lab InternacionalB de CV's Sloan Ratio for the quarter that ended in Sep. 2024 was 0.29%.

As of Sep. 2024, Genomma Lab InternacionalB de CV has a Sloan Ratio of 0.29%, indicating the company is in the safe zone and there is no funny business with accruals.


Genomma Lab InternacionalB de CV Sloan Ratio % Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Sloan Ratio % Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.17 1.65 2.81 -0.82 -4.15

Genomma Lab InternacionalB de CV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -4.13 -1.80 -0.43 0.29

Competitive Comparison of Genomma Lab InternacionalB de CV's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Sloan Ratio % falls into.



Genomma Lab InternacionalB de CV Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Genomma Lab InternacionalB de CV's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(63.915-132.378
--17.804)/1221.762
=-4.15%

Genomma Lab InternacionalB de CV's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(86.818-137.474
--54.061)/1193.9
=0.29%

Genomma Lab InternacionalB de CV's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -3.603 (Dec. 2023 ) + 22.421 (Mar. 2024 ) + 34.478 (Jun. 2024 ) + 33.522 (Sep. 2024 ) = $86.8 Mil.
Genomma Lab InternacionalB de CV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 48.278 (Dec. 2023 ) + -7.619 (Mar. 2024 ) + 22.493 (Jun. 2024 ) + 74.322 (Sep. 2024 ) = $137.5 Mil.
Genomma Lab InternacionalB de CV's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -18.652 (Dec. 2023 ) + -2.156 (Mar. 2024 ) + -3.018 (Jun. 2024 ) + -30.235 (Sep. 2024 ) = $-54.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, Genomma Lab InternacionalB de CV has a Sloan Ratio of 0.29%, indicating the company is in the safe zone and there is no funny business with accruals.


Genomma Lab InternacionalB de CV Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.